关注
Giuseppe (Nello) Ambrosio
Giuseppe (Nello) Ambrosio
Cardiology, University of Perugia School of Medicine
在 unipg.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Telmisartan, ramipril, or both in patients at high risk for vascular events
PJ Yusuf S, Teo KK
New England Journal of Medicine 358, 1547-59, 2008
4948*2008
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus
S BM
New England Journal of Medicine 369, 1317, 2013
42372013
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
JB Green, MA Bethel, PW Armstrong, JB Buse, SS Engel, J Garg, R Josse, ...
New England Journal of Medicine 373 (3), 232-242, 2015
31532015
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
FG Anker Stefan D, Butler J
N Engl J Med 385, 2021
3089*2021
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
MS Sabatine
NEW ENGLAND JOURNAL OF MEDICINE 352, 1179, 2005
29162005
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
HAF Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan ...
N Engl J Med 377 (13), 1228-1239, 2017
1997*2017
Bivalirudin for patients with acute coronary syndromes
GW Stone, BT McLaurin, DA Cox, ME Bertrand, AM Lincoff, JW Moses, ...
New England Journal of Medicine 355 (21), 2203-2216, 2006
17512006
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
FR Fox K, Ford I, Steg PG, Tendera M, B Investigators.
Lancet 372, 807, 2008
14742008
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised …
TK Yusuf S
Lancet 372, 1174-83, 2008
12312008
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
MT Roe
New England Journal of Medicine, 2012
10912012
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
A PW
New England Journal of Medicine 382, 1883-1893, 2020
10712020
Microcirculation in Hypertension A New Target for Treatment?
BI Levy, G Ambrosio, AR Pries, HAJ Struijker-Boudier
Circulation 104 (6), 735-740, 2001
9642001
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
P Tricoci, Z Huang, C Held, DJ Moliterno, PW Armstrong, F Van de Werf, ...
New England Journal of Medicine 366 (1), 20-33, 2012
9062012
Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term …
O Chioncel, M Lainscak, PM Seferovic, SD Anker, MG Crespo‐Leiro, ...
European journal of heart failure 19 (12), 1574-1585, 2017
8882017
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
M Konstam
Lancet 374, 1840, 2009
8032009
From endothelial dysfunction to atherosclerosis
S Sitia, L Tomasoni, F Atzeni, G Ambrosio, C Cordiano, A Catapano, ...
Autoimmunity reviews 9 (12), 830-834, 2010
7522010
Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow.
G Ambrosio, JL Zweier, C Duilio, P Kuppusamy, G Santoro, PP Elia, ...
Journal of Biological Chemistry 268 (25), 18532-18541, 1993
6551993
Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow.
G Ambrosio, HF Weisman, JA Mannisi, LC Becker
Circulation 80 (6), 1846-1861, 1989
6261989
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Teerlink JR
N Engl J Med 384, 105-116, 2021
5482021
Reperfusion injury: experimental evidence and clinical implications
G Ambrosio, I Tritto
American heart journal 138 (2), S69-S75, 1999
4911999
系统目前无法执行此操作,请稍后再试。
文章 1–20